TP53 and breast cancer: Moreover, in the prognostic and predictive cohort combined (n = 942; n = 141 BC patients in both cohorts), none of the 11 patients with bi-allelic inactivation of CHEK2 had a TP53 mutation (P = 0.14), again confirming what we observed among pBC and mBC genomes.